- Home
- GORO vs CUE Comparison
GORO vs CUE Comparison
Compare GORO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GORO | CUE |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 27.1M |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GORO | CUE |
|---|---|---|
| Price | $1.42 | $0.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.75 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 3.2M | 355.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,726,000.00 | $9,287,000.00 |
| Revenue This Year | $9.04 | N/A |
| Revenue Next Year | $93.07 | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.34 | $0.23 |
| 52 Week High | $1.87 | $1.17 |
Technical Indicators
Market Signals| Indicator | GORO | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 44.28 |
| Support Level | $1.27 | $0.28 |
| Resistance Level | $1.81 | $0.36 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 15.39 | 38.58 |
Price Performance
Historical ComparisonAbout GORO Gold Resource Corporation
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.